Life Science Compliance Update

September

2017

September 2017: Life Science Compliance Update

Written by , Posted in September 2017 LSC Update, This Month in Compliance

The full text of the entire issue is now available to our subscribers. If you are a subscriber please log in now. You may also buy this issue by clicking on the button below.


   or   

July 2017 LSCU Cover

Issue Summary

This month we feature an extensive, in-depth look into the drug distribution verification law in Ohio, which will significantly impact product sampling in the state. We also take a look a mid-year look at False Claims Act settlement and the recent data from U.S. DOJ’s FCPA Pilot Program. Rounding out the issue are a look at two recent FCA cases involving Fresenius and Celgene, both of which have the promise to impact how FCA cases are pursued in the future.


Feature Article

Arrow

Ohio Drug Distribution Verification: America’s Key Battleground State Shakes Up the Pharmaceutical Supply Chain
Nicodemo (Nico) Fiorentino, Esq., Manager, Research & Compliance, for G&M Health LLC; John Patrick Oroho, Esq., Executive Vice President and Chief Strategy Officer, Porzio Life Sciences, LLC, Principal, Porzio, Bromberg & Newman PC; Teresita Weiss, Ph.D., J.D., Sr. Vice President, Regulatory Affairs and Compliance, for J. Knipper and Company, Inc.; Bryan Andrews, Director of Sales Operations, MedPro Systems LLC.
Abstract

Issue Articles

Arrow

False Claims Act Mid-Year Review: Significant Life Science Settlements, Post-Escobar Developments & Industry Round Up
John Kelly, Julia Tamulis, and Robert Platt
Abstract

Arrow

To Disclose or Not to Disclose…. That is the Question: The DOJ’s FCPA Pilot Program – Insights from Year One and Beyond
Mark Scallon, Partner, FRA Life Sciences, Jenny McVey, Manager, FRA Life Sciences and Jimmy Ko, Senior Associate, Forensic Risk Alliance
Abstract

Arrow

Fresenius to the U.S. Government: When It Comes to the FCA, You Snooze You Lose
Robert N. Wilkey, Esq., Staff Writer for Life Science Compliance Update
Abstract

Arrow

Taking Center Stage – Washington State’s Medicaid Fraud Control Unit, the False Claims Act and Celegene
Robert N. Wilkey, Esq., Staff Writer for Life Science Compliance Update
Abstract

Menu Title